SRR6013589
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.490
- WNT_BETA_CATENIN_SIGNALING+0.420
- MYC_TARGETS_V2+0.410
- ANGIOGENESIS+0.310
- APICAL_SURFACE+0.250
- HEDGEHOG_SIGNALING+0.250
- E2F_TARGETS+0.240
- IL2_STAT5_SIGNALING+0.240
- APICAL_JUNCTION+0.220
- MYOGENESIS+0.210
Top 10 suppressed
- PROTEIN_SECRETION-0.460
- CHOLESTEROL_HOMEOSTASIS-0.390
- PANCREAS_BETA_CELLS-0.390
- INTERFERON_ALPHA_RESPONSE-0.370
- FATTY_ACID_METABOLISM-0.350
- INTERFERON_GAMMA_RESPONSE-0.210
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.210
- OXIDATIVE_PHOSPHORYLATION-0.200
- ADIPOGENESIS-0.170
- HEME_METABOLISM-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 20040090.TNBC | — | D | 0.796 |
| 2 | TCGA-22-4604-01A-01R-1201-07 | — | cohortSQ2 | 0.738 |
| 3 | e040e6c8-34e5-44fb-a6f3-c247009fccfc | — | — | 0.724 |
| 4 | C3L-02660 | — | cohortSQ1 | 0.712 |
| 5 | TCGA-AC-A7VC-01A-11R-A352-07 | — | A | 0.709 |
| 6 | R99 | — | — | 0.703 |
| 7 | TCGA-CV-5431-01A-01R-1514-07 | — | — | 0.701 |
| 8 | TCGA-F7-8298-01A-11R-2403-07 | — | — | 0.698 |
| 9 | SRR23303757 | — | — | 0.694 |
| 10 | BS_C41DJZ1F | high-grade glioma | — | 0.686 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.490 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.420 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.410 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.310 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.250 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.250 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.240 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.240 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.220 | Inavolisib | — uncovered |
| MYOGENESIS | 0.210 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.210 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.190 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.180 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.150 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.150 | Inavolisib | — uncovered |
| HYPOXIA | 0.130 | Idelalisib | — uncovered |
| COAGULATION | 0.050 | Binimetinib | — uncovered |
| DNA_REPAIR | 0.050 | Idelalisib | — uncovered |